acquired
Stage
1999
Founded
2
Investors
About
Lysogene is a biopharmaceutical gene therapy company focused on developing therapies for rare, inherited neurodegenerative diseases affecting the central nervous system, particularly in children, using adeno-associated viral (AAV) vectors to deliver functional genes.
Explore Lysogene's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.